An Australian-led study reported in the January 25, 2021, online edition of Nature Immunology has identified a new immunomodulatory pathway within the gut-lung axis that enhances microbial tyrosine metabolism, which could be targeted to treat or prevent atopic asthma and other inflammatory diseases.

San Diego area startup Endeavor Biomedicines Inc. launched in January 2021, with a $62 million series A financing from Omega Funds, Longitude Capital and its own management team. The company is working on one asset, ENV-101 or taladegib, a small-molecule inhibitor targeting the Hedgehog pathway, which it plans to develop for the treatment of idiopathic pulmonary fibrosis (IPF).